Denali Therapeutics
DNLI
148 hedge funds and large institutions have $2B invested in Denali Therapeutics in 2020 Q2 according to their latest regulatory filings, with 32 funds opening new positions, 54 increasing their positions, 37 reducing their positions, and 11 closing their positions.
191% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 11
158% more call options, than puts
Call options by funds: $837K | Put options by funds: $324K
46% more repeat investments, than reductions
Existing positions increased: 54 | Existing positions reduced: 37
42% more capital invested
Capital invested by funds: $1.41B → $2B (+$592M)
16% more funds holding
Funds holding: 128 → 148 (+20)
2.02% more ownership
Funds ownership: 76.34% → 78.36% (+2%)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
Top Buyers
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$33.2M |
| 2 |
BlackRock
New York
|
+$23.3M |
| 3 |
State Street
Boston,
Massachusetts
|
+$13.1M |
| 4 |
CCM
CAAS Capital Management
New York
|
+$12.3M |
| 5 |
UBS AM
Chicago,
Illinois
|
+$10M |
Top Sellers
| 1 |
CM
Crestline Management
Fort Worth,
Texas
|
-$45.2M |
| 2 |
PA
Perceptive Advisors
New York
|
-$14.9M |
| 3 |
BCM
Bratton Capital Management
Fort Worth,
Texas
|
-$11.9M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$9.68M |
| 5 |
MWNA
Marshall Wace North America
New York
|
-$7.61M |
DNLI Hedge Fund Activity: Q2 2020 in Review
148 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Denali Therapeutics (DNLI) for Q2 2020, worth a combined $2B — up 42% from $1.41B a quarter earlier.
Buyers outnumbered sellers: 32 funds opened new DNLI positions and 11 closed out — a net gain of 21 holders — while 54 added to existing stakes and 37 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $33.2M. The largest seller was Crestline Management, cutting an estimated $45.2M.
- 148 institutional investors held Denali Therapeutics (DNLI) as of Q2 2020, up from 128 in Q1 2020.
- Funds reported $2B of Denali Therapeutics stock for Q2 2020, up 42% quarter-over-quarter.
- 32 funds opened new Denali Therapeutics positions in Q2 2020 and 11 closed out, a net change of +21 holders.
- The largest Denali Therapeutics buyer in Q2 2020 was T. Rowe Price Associates, an estimated $33.2M added.
- The largest Denali Therapeutics seller in Q2 2020 was Crestline Management, an estimated $45.2M sold.
Based on aggregated 13F filings for Q2 2020.